Table 3.

Univariate association of baseline patient and disease characteristics with survival and response

OSResponse
FactorAlive at 1 year, % (95% CI)HRPORR, %P
Traditional factors
 ECOG PS
  070 (65.6–74.7)0.56<0.001360.100
  151 (43.6–57.7)29
 LDH level
  Normal79 (74.0–82.8)0.37<0.00143<0.001
  Elevated44 (37.2–49.8)21
 M stage
  M0, M1a, or M1b86 (78.6–91.4)0.40<0.00150<0.001
  M1c58 (53.6–62.6)29
 Age
  Below median (≤61 years)63 (56.7–67.8)0.930.534320.464
  Above median (>61 years)65 (59.6–70.6)35
 Sex
  Male64 (58.5–68.4)0.910.400360.180
  Female64 (57.6–70.4)30
Other factors
BRAFV600 mutation status
  Wild type66 (60.8–69.7)0.820.113360.036
  Mutant59 (50.4–67.2)26
 Prior brain metastases
  Yes68 (53.2–79.0)0.840.391341.000
  No64 (59.2–67.4)34
 Prior ipilimumab treatment
  Naïve68 (62.4–73.5)0.880.234380.028
  Exposed60 (54.2–65.2)29
 Number of prior therapies
  070 (61.8–77.3)0.770.053430.009
  ≥162 (57.3–66.3)31
 Pembrolizumab dose and schedule
  10 mg/kg Q2W63 (55.5–70.1)0.970.704370.522
  10 mg/kg Q3W64 (57.6–69.1)1.0232
  2 mg/kg Q3W65 (56.8–72.5)32
 BTS (SLD)
  Below median (≤10.2 cm)80 (74.6–83.9)0.38<0.00144<0.001
  Above median (>10.2 cm)48 (42.0–53.6)23
 Tumor PD-L1 status
  Positive69 (63.6–73.4)0.51<0.00139<0.001
  Negative45 (35.4–54.4)13
 Site of metastasis
  Lung only89 (80.4–94.3)0.29<0.00162<0.001
  Liver, with or without any other sites53 (46.2–60.1)1.0022
  Other64 (58–68.9)0.6533
  • Abbreviations: CI, confidence interval; Q2W, every 2 weeks; Q3W, every 3 weeks; SLD, sum of the longest diameters.